<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04625764</url>
  </required_header>
  <id_info>
    <org_study_id>CSI17</org_study_id>
    <nct_id>NCT04625764</nct_id>
  </id_info>
  <brief_title>Ticagrelor Removal Study Using CytoSorb® 300 mL Device During CPB in Patients Undergoing Emergent Cardiothoracic Surgery</brief_title>
  <acronym>CyTation</acronym>
  <official_title>A Prospective, Open, Multi-center, Single-arm Study to Demonstrate the Feasibility of the CytoSorb® 300 mL Device to Remove Ticagrelor During Cardiopulmonary Bypass in Patients on Ticagrelor Undergoing Emergent Cardiothoracic Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CytoSorbents Europe GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CytoSorbents Europe GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of CyTation is to demonstrate intra-operative removal of ticagrelor by CytoSorb®&#xD;
      hemadsorption in patients on ticagrelor undergoing emergent cardiothoracic surgery requiring&#xD;
      CPB, using platelet reactivity to adenosine diphosphate (ADP) as a pharmacodynamics surrogate&#xD;
      measure of ticagrelor levels in blood.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 23, 2021</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet reactivity</measure>
    <time_frame>8 hours</time_frame>
    <description>Proportion of patients with post-operative platelet reactivity to ADP above the level associated with increased bleeding risk (≥ 22 ADP-induced platelet aggregation units (AUC in units)) measured on the MEA platform immediately after CPB compared to immediately before CPB.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>patients on ticagrelor undergoing emergent cardiothoracic surgery requiring CPB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sampling and analysis</intervention_name>
    <description>Blood sampling for pharmacokinetics (Plasma ticagrelor concentrations and its metabolite) and MEA platform testing (ADPtest, TRAPtest)</description>
    <arm_group_label>patients on ticagrelor undergoing emergent cardiothoracic surgery requiring CPB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Males and females aged ≥18 years&#xD;
&#xD;
          -  Patients treated with ticagrelor&#xD;
&#xD;
          -  Emergency Coronary Artery Bypass Graft (CABG) surgery&#xD;
&#xD;
          -  Cardiothoracic surgery requiring CPB ≤24 hours following the last dose of ticagrelor&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any cardiothoracic surgery &gt;24 hours after last dose of ticagrelor&#xD;
&#xD;
          -  Resuscitation&#xD;
&#xD;
          -  Any pre-operative coagulopathy unrelated to ticagrelor or standard of care (SoC) to&#xD;
             undergo surgery with CPB&#xD;
&#xD;
          -  Sepsis (according to Sepsis 3.0 definition)&#xD;
&#xD;
          -  Malignant tumor&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) &lt; 20%&#xD;
&#xD;
          -  History or presence of significant pulmonary, hepatic, renal, hematologic,&#xD;
             gastrointestinal, endocrine, immunologic, neurologic, or psychiatric disease which, in&#xD;
             the opinion of the Investigator, increases risk to the patient or could confound the&#xD;
             results of the study&#xD;
&#xD;
          -  Presence of end-stage renal disease or currently receiving renal replacement therapy&#xD;
&#xD;
          -  Patients with a history of major organ transplantation&#xD;
&#xD;
          -  Patients in acute sickle cell crisis&#xD;
&#xD;
          -  Patients concurrently requiring immunosuppressive therapy, with the exception of&#xD;
             corticosteroids, or who are profoundly immune suppressed (e.g. CD4 &lt; 200 or&#xD;
             neutropenia with ANC &lt; 1000/μL)&#xD;
&#xD;
          -  Women of childbearing potential with a positive pregnancy test performed during the&#xD;
             current admission or who are lactating. Women are considered not of child bearing&#xD;
             potential if they have been sterilized at least 6 months prior to the study or if they&#xD;
             are post-menopausal, defined as amenorrhea for at least 12 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kambiz Hassan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asklepios Kliniken Hamburg gGmbH, Asklepios Klinik St. Georg, Abteilung für Herzchirurgie/ Chefarzt Prof. Michael Schmoeckel, Lohmühlenstr. 5, 20099 Hamburg/Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sven Giersdorf, Ph.D.</last_name>
    <phone>+49 30 65499145</phone>
    <email>clinical@cytosorbents.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Thielmann, Prof. MD</last_name>
    </contact>
    <investigator>
      <last_name>Matthias Thielmann, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asklepios Hospital St. Georg Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kambiz Hassan, MD</last_name>
    </contact>
    <investigator>
      <last_name>Kambiz Hassan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Jena</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mahmoud Diab, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mahmoud Diab, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut National de Chirurgie Cardiaque et de Cardiologie Interventionnelle</name>
      <address>
        <city>Luxembourg</city>
        <zip>1210</zip>
        <country>Luxembourg</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaus Kallenbach, Prof. MD</last_name>
    </contact>
    <investigator>
      <last_name>Klaus Kallenbach, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Luxembourg</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 6, 2020</study_first_submitted>
  <study_first_submitted_qc>November 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2020</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiopulmonary bypass</keyword>
  <keyword>CPB</keyword>
  <keyword>Ticagrelor removal</keyword>
  <keyword>CytoSorb</keyword>
  <keyword>Platelet reactivity</keyword>
  <keyword>MEA platform test</keyword>
  <keyword>Intensive care medicine</keyword>
  <keyword>Hemadsorbtion</keyword>
  <keyword>Extracorporeal blood purification</keyword>
  <keyword>Coronary Artery Bypass Grafting</keyword>
  <keyword>CABG</keyword>
  <keyword>Cardiac Surgery</keyword>
  <keyword>Aortic valve replacement</keyword>
  <keyword>Mitral valve replacement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

